Back to top
more

Immunovant (IMVT)

(Delayed Data from NSDQ)

$26.63 USD

26.63
1,566,949

-1.42 (-5.06%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $26.64 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Cash flow Statements

Research for IMVT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Immunovant, Inc falls in the month of March.

All data in Millions except Per Share data.

Cash Flow From Operations, Investments & Financial Activities

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Cash Flow From Operations, Investments & Financial
Activities		          
Net Income (Loss) -259.34 -210.96 -156.73 -107.43 -66.39
Depreciation/Amortization & Depletion 0.23 0.19 0.13 0.07 0.02
Net Change from Assets/Liabilities 2.63 -10.85 15.14 4.57 4.81
Net Cash from Discontinued Operations 0.00 0.00 0.00 0.00 0.00
Other Operating Activities 42.25 33.43 35.35 19.47 8.20
Net Cash From Operating Activities -214.23 -188.19 -106.11 -83.33 -53.36
Property & Equipment -0.36 -0.20 -0.25 -0.21 -0.03
Acquisition/ Disposition of Subsidiaries 0.00 0.00 0.00 0.00 0.00
Investments 0.00 0.00 0.00 0.00 0.00
Other Investing Activities 0.00 0.00 0.00 0.00 0.00
Net Cash from Investing Activities -0.36 -0.20 -0.25 -0.21 -0.03

Uses of Funds

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Issuance (Repurchase) of Capital Stock 478.44 71.16 0.00 386.44 0.00
Issuance (Repayment) of Debt 0.00 0.00 0.00 0.00 32.50
Increase (Decrease) Short-Term Debt 0.00 0.00 200.00 -3.19 5.41
Payment of Dividends & Other Distributions 0.00 0.00 0.00 0.00 0.00
Other Financing Activities -6.01 -0.27 0.13 -0.14 109.07
Net Cash from Financing Activities 472.43 70.89 200.13 383.11 146.97
Effect of Exchange Rate Changes 0.99 0.22 -0.09 0.00 0.00
Net Change In Cash & Equivalents 258.83 -117.29 93.67 299.58 93.59
Cash at Beginning of Period 376.53 493.82 400.15 100.57 6.99
Cash at End of Period 635.37 376.53 493.82 400.15 100.57
Diluted Net EPS -1.88 -1.71 -1.43 -1.22 -1.54

Fiscal Year End for Immunovant, Inc falls in the month of March.

All data in Millions except Per Share data.

Cash Flow From Operations, Investments & Financial Activities

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Cash Flow From Operations, Investments & Financial
Activities		          
Net Income (Loss) -196.27 -87.15 -259.34 -184.02 -132.60
Depreciation/Amortization & Depletion 0.17 0.00 0.23 0.17 0.11
Net Change from Assets/Liabilities 5.02 -2.65 2.63 -2.99 3.26
Net Cash from Discontinued Operations NA 0.00 0.00 0.00 0.00
Other Operating Activities 26.24 13.60 42.25 32.32 21.80
Net Cash From Operating Activities -164.85 -76.20 -214.23 -154.53 -107.43
Property & Equipment -0.38 -0.18 -0.36 -0.21 -0.08
Acquisition/ Disposition of Subsidiaries NA 0.00 0.00 0.00 0.00
Investments NA 0.00 0.00 0.00 0.00
Other Investing Activities NA 0.00 0.00 0.00 0.00
Net Cash from Investing Activities -0.38 -0.18 -0.36 -0.21 -0.08

Uses of Funds

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Issuance (Repurchase) of Capital Stock 1.42 0.69 478.44 476.89 1.04
Issuance (Repayment) of Debt NA 0.00 0.00 0.00 0.00
Increase (Decrease) Short-Term Debt NA 0.00 0.00 0.00 0.00
Payment of Dividends & Other Distributions NA 0.00 0.00 0.00 0.00
Other Financing Activities NA 0.00 -6.01 -6.01 0.00
Net Cash from Financing Activities 1.42 0.69 472.43 470.88 1.04
Effect of Exchange Rate Changes 1.38 0.34 0.99 -1.74 -0.13
Net Change In Cash & Equivalents -162.42 -75.36 258.83 314.41 -106.60
Cash at Beginning of Period 635.37 635.37 376.53 376.53 376.53
Cash at End of Period 472.94 560.01 635.37 690.94 269.93
Diluted Net EPS -0.74 -0.60 -0.50 -0.36 -0.45